Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1986 1
1987 1
1988 1
1990 1
2011 1
2012 2
2013 1
2014 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
In reply.
Kammili Y, McCann-Pineo M, Witz LR, Li T, Hatchell M, Sud P. Kammili Y, et al. Among authors: hatchell m. Ann Emerg Med. 2025 Oct;86(4):448-449. doi: 10.1016/j.annemergmed.2025.05.013. Ann Emerg Med. 2025. PMID: 40975547 No abstract available.
Citalopram for agitation in Alzheimer's disease: design and methods.
Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group. Drye LT, et al. Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1. Alzheimers Dement. 2012. PMID: 22301195 Free PMC article. Clinical Trial.
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Drye LT, et al. PLoS One. 2014 Jun 10;9(6):e98426. doi: 10.1371/journal.pone.0098426. eCollection 2014. PLoS One. 2014. PMID: 24914549 Free PMC article. Clinical Trial.
Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.
Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; Depression in Alzheimer’s Disease Study–2 Research Group. Munro CA, et al. Am J Geriatr Psychiatry. 2012 Dec;20(12):1036-44. doi: 10.1097/JGP.0b013e31826ce4c5. Am J Geriatr Psychiatry. 2012. PMID: 23032478 Free PMC article. Clinical Trial.
14 results